(OFIX) Orthofix Medical - Ratings and Ratios
Spine Fixation, Bone Stimulators, Biologics, Extremity Hardware
OFIX EPS (Earnings per Share)
OFIX Revenue
Description: OFIX Orthofix Medical
Orthofix Medical Inc. is a medical technology company operating globally, with a presence in multiple countries including the US, Italy, Germany, and Brazil. The company is divided into two main segments: Global Spine and Global Orthopedics, both of which focus on developing and marketing medical devices and solutions for various orthopedic and spinal conditions.
The companys product portfolio includes bone growth stimulation devices, spine fixation and motion preservation implant products, and biological products such as demineralized bone matrices and synthetic bone void fillers. Additionally, Orthofix Medical Inc. offers navigation technologies, including the 7D flash navigation system for spine and cranial procedures, which is a significant innovation in the field of orthopedic surgery.
From a financial perspective, Orthofix Medical Inc. has a market capitalization of $436.87M USD, indicating a mid-cap company with a relatively stable presence in the market. The forward P/E ratio of 20.04 suggests that investors have moderate expectations for the companys future earnings growth. However, the Return on Equity (RoE) of -28.15% is a concern, indicating that the company is currently not generating sufficient profits to justify its equity.
To further analyze the companys performance, some key performance indicators (KPIs) to consider are: Revenue Growth Rate, Gross Margin, Operating Margin, and Cash Flow Conversion Rate. A review of these KPIs would provide insights into the companys ability to generate revenue, maintain profitability, and manage its cash flows effectively. Additionally, metrics such as Debt-to-Equity Ratio and Interest Coverage Ratio would be useful in assessing the companys financial leverage and ability to meet its debt obligations.
In terms of potential investment opportunities, a closer look at Orthofix Medical Inc.s product pipeline, research and development (R&D) expenses, and competitive positioning within the orthopedic and spine markets would be necessary. The companys ability to innovate and expand its product offerings, while maintaining a strong financial position, will be critical in determining its long-term success.
OFIX Stock Overview
| Market Cap in USD | 592m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1992-04-24 |
OFIX Stock Ratings
| Growth Rating | -61.7% |
| Fundamental | 37.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -25.0% |
| Analyst Rating | 4.0 of 5 |
OFIX Dividends
Currently no dividends paidOFIX Growth Ratios
| Growth Correlation 3m | 88.2% |
| Growth Correlation 12m | -68.2% |
| Growth Correlation 5y | -86.7% |
| CAGR 5y | -12.25% |
| CAGR/Max DD 3y | -0.21 |
| CAGR/Mean DD 3y | -0.42 |
| Sharpe Ratio 12m | -1.31 |
| Alpha | -26.39 |
| Beta | 0.422 |
| Volatility | 44.41% |
| Current Volume | 433.5k |
| Average Volume 20d | 433.5k |
| Stop Loss | 14.2 (-3.7%) |
| Signal | -1.11 |
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (-123.7m TTM) > 0 and > 6% of Revenue (6% = 48.5m TTM) |
| FCFTA 0.00 (>2.0%) and ΔFCFTA 12.28pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 30.59% (prev 29.82%; Δ 0.77pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.03 (>3.0%) and CFO 28.6m > Net Income -123.7m (YES >=105%, WARN >=100%) |
| Net Debt (139.1m) to EBITDA (3.68m) ratio: 37.78 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.67 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (39.5m) change vs 12m ago 3.90% (target <= -2.0% for YES) |
| Gross Margin 68.43% (prev 65.52%; Δ 2.91pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 94.12% (prev 87.49%; Δ 6.63pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -3.29 (EBITDA TTM 3.68m / Interest Expense TTM 28.6m) >= 6 (WARN >= 3) |
Altman Z'' -1.07
| (A) 0.30 = (Total Current Assets 395.8m - Total Current Liabilities 148.4m) / Total Assets 837.2m |
| (B) -0.41 = Retained Earnings (Balance) -343.3m / Total Assets 837.2m |
| (C) -0.11 = EBIT TTM -94.1m / Avg Total Assets 859.6m |
| (D) -0.89 = Book Value of Equity -338.5m / Total Liabilities 378.8m |
| Total Rating: -1.07 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 36.97
| 1. Piotroski 4.0pt = -1.0 |
| 2. FCF Yield 0.07% = 0.03 |
| 3. FCF Margin 0.06% = 0.01 |
| 4. Debt/Equity 0.35 = 2.44 |
| 5. Debt/Ebitda 43.69 = -2.50 |
| 6. ROIC - WACC -21.22% = -12.50 |
| 7. RoE -25.43% = -2.50 |
| 8. Rev. Trend 77.59% = 5.82 |
| 9. EPS Trend -56.64% = -2.83 |
What is the price of OFIX shares?
Over the past week, the price has changed by +0.34%, over one month by +3.65%, over three months by +34.95% and over the past year by -10.77%.
Is Orthofix Medical a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of OFIX is around 13.53 USD . This means that OFIX is currently overvalued and has a potential downside of -8.27%.
Is OFIX a buy, sell or hold?
- Strong Buy: 2
- Buy: 1
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the OFIX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 22.6 | 52.9% |
| Analysts Target Price | 22.6 | 52.9% |
| ValueRay Target Price | 14.8 | 0.3% |
Last update: 2025-09-03 04:44
OFIX Fundamental Data Overview
CCE Cash And Equivalents = 65.6m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 20.0401
P/S = 0.7313
P/B = 1.2908
P/EG = 0.3269
Beta = 0.819
Revenue TTM = 809.0m USD
EBIT TTM = -94.1m USD
EBITDA TTM = 3.68m USD
Long Term Debt = 157.0m USD (from longTermDebt, last quarter)
Short Term Debt = 3.85m USD (from shortTermDebt, last quarter)
Debt = 160.9m USD (Calculated: Short Term 3.85m + Long Term 157.0m)
Net Debt = 139.1m USD (from netDebt column, last quarter)
Enterprise Value = 686.9m USD (591.6m + Debt 160.9m - CCE 65.6m)
Interest Coverage Ratio = -3.29 (Ebit TTM -94.1m / Interest Expense TTM 28.6m)
FCF Yield = 0.07% (FCF TTM 461.0k / Enterprise Value 686.9m)
FCF Margin = 0.06% (FCF TTM 461.0k / Revenue TTM 809.0m)
Net Margin = -15.29% (Net Income TTM -123.7m / Revenue TTM 809.0m)
Gross Margin = 68.43% ((Revenue TTM 809.0m - Cost of Revenue TTM 255.4m) / Revenue TTM)
Tobins Q-Ratio = -2.03 (set to none) (Enterprise Value 686.9m / Book Value Of Equity -338.5m)
Interest Expense / Debt = 2.46% (Interest Expense 3.95m / Debt 160.9m)
Taxrate = 21.0% (US default)
NOPAT = -94.1m (EBIT -94.1m, no tax applied on loss)
Current Ratio = 2.67 (Total Current Assets 395.8m / Total Current Liabilities 148.4m)
Debt / Equity = 0.35 (Debt 160.9m / last Quarter total Stockholder Equity 458.3m)
Debt / EBITDA = 43.69 (Net Debt 139.1m / EBITDA 3.68m)
Debt / FCF = 349.0 (Debt 160.9m / FCF TTM 461.0k)
Total Stockholder Equity = 486.4m (last 4 quarters mean)
RoA = -14.78% (Net Income -123.7m, Total Assets 837.2m )
RoE = -25.43% (Net Income TTM -123.7m / Total Stockholder Equity 486.4m)
RoCE = -14.63% (Ebit -94.1m / (Equity 486.4m + L.T.Debt 157.0m))
RoIC = -14.85% (NOPAT -94.1m / Invested Capital 633.8m)
WACC = 6.37% (E(591.6m)/V(752.5m) * Re(7.57%)) + (D(160.9m)/V(752.5m) * Rd(2.46%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 6.34%
Discount Rate = 7.57% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 80.03% ; FCFE base≈461.0k ; Y1≈523.4k ; Y5≈715.6k
Fair Price DCF = 0.31 (DCF Value 12.4m / Shares Outstanding 39.5m; 5y FCF grow 15.76% → 3.0% )
EPS Correlation: -56.64 | EPS CAGR: -13.55% | SUE: 0.10 | # QB: False
Revenue Correlation: 77.59 | Revenue CAGR: 23.37%
Additional Sources for OFIX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle